Signal active
Bio
Brad Bolzon is both a Menlo Park and Basel, Switzerland-based Managing Director.Brad brings more than thirteen years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early-stage biotech investing with a particular emphasis on new company start-ups.Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with F. Hoffmann-La Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened its product pipeline.Previously, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development.
CURRENT BOARD SEATS:Anaphore, FLAP, Flexion, Inception, Panmira, Quanticel, EuroVentures, a wholly-owned start-up incubator of Versant Ventures.PREVIOUS BOARD INVOLVEMENT:Amira (acquired), BioTie, Metabolex, Okairos (acquired), Speedel (acquired), Synosia (acquired).He was learned MS for University of Toronto,and PhD for University of Toronto,Ottawa Heart Institute, post-doctoral research.
Location
N/A
Social
N/A
Primary Organization
1999
375
102
105
11-50
Financial Services, Venture Capital, Health Care
Jobs history
0
N/A
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Bradley Bolzon is the Managing Director at Versant Ventures. With a background in Financial Services, Bradley Bolzon has a rich history of leadership and innovation. Bradley Bolzon studied MS unknown @ University of Toronto. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
8
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Apr 29, 2015 | CRISPR Therapeutics | Series A - CRISPR Therapeutics | Versant Ventures | 35.0M |
Apr 30, 2015 | CRISPR Therapeutics | Series B - CRISPR Therapeutics | Versant Ventures | 29.0M |
Mar 28, 2018 | Tempest Therapeutics | Series B - Tempest Therapeutics | Versant Ventures | 70.0M |
Apr 27, 2022 | Tempest Therapeutics | Post-IPO Equity - Tempest Therapeutics | Versant Ventures | 15.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.